PRDX2 and nasopharyngeal carcinoma: We here measured the combination of autoantibodies against PRDX2 and PRDX3 and VCA-IgA in early-stage NPC and normal controls resulting in 50.0% sensitivity with a robust specificity of 95.0% (Table 3).